Bora Pharmaceuticals Ophthalmic Inc. Taoyuan plant, Research Building – FDA 483, Nov 4, 2022
Synpac-Kingdom Pharmaceutical Company Ltd in Taoyuan City, Taiwan, was cited for significant deficiencies during an FDA inspection. Observations included a lack of written procedures for production and process controls, inadequate validation of aseptic processes for sterile drug products, and a failure to thoroughly investigate unexplained discrepancies and out-of-specification results. These issues indicate a lack of robust quality control and assurance for drug product identity, strength, quality, and purity.
- Inspection date
- November 4, 2022
- Product type
- drugs
ID · dafae910-e712-42ce-87cf-5ae6014f567e
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.